Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Dave who wrote (257)	9/6/2001 3:22:26 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Lots of variables with that one. Don't know if there are typical numbers or not. Lots depend on the targeted condition(s) and the number of people in the various trials. Usually the numbers are low for the PI and PII trials, but the PIII ones are the proof in the pudding and just enrollment can take months. That is in addition to the data collection and analysis that is needed in order to file for an new drug approval. Your best bet is to look at the Vion site for info on the trial dates and try to extrapolate from that. I don't think the approval/non-approval call will be until at least Q2, '03 for these drugs. Triapine has a bit of a jump since the PII has started. I can not really look much further at this time. Jim